HOME >> MEDICINE >> NEWS
Statins could reduce stroke risk by a third

Statins-drugs that lower LDL cholesterol-substantially reduce the incidence of ischaemic stroke among high-risk individuals, conclude authors of a study in this weeks issue of THE LANCET.

Cholesterol lowering with statins is of known benefit for people at increased risk of heart attack. However, current treatment guidelines do not recommend that doctors take account of a person's risk of stroke when deciding whether to use statin therapy. Rory Collins from the Clinical Trial Service Unit, Oxford, UK, and colleagues report detailed results from a five-year study of the effect of simvastatin or placebo among 20,536 people with either a history of stroke or other cerebrovascular disease (3280 people) or at high risk of stroke for other reasons (17,256 people).

Participants were randomly assigned 40 mg simvastatin daily or matching placebo for five years, which yielded an average reduction in LDL cholesterol of 1 mmol/litre. There was a very definite 25% proportional reduction in the incidence of stroke among patients in the simvastatin group (444 strokes; 4.3%) compared with those in the placebo group (585 strokes; 5.7%). This reflected a 30% proportional reduction in the incidence of 'ischaemic' strokes (ie, due to artery blockage in the brain), with no apparent difference in the incidence of 'haemorrhagic' strokes (ie, due to bleeding into the brain). Although the stroke rate was not significantly reduced by simvastatin among participants with a history of cerebrovascular disease, there was a substantial reduction in the combined risk of all major vascular events (ie, heart attacks, strokes, and revascularisation procedures) among these patients.

Rory Collins comments: "This study shows that statin therapy rapidly reduces the incidence not only of heart attacks but also of ischaemic strokes, with no adverse effect on haemorrhagic strokes, even among individuals who do not have high cholesterol concentrations. Allocation to 40 mg simvast
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
4-Mar-2004


Page: 1 2

Related medicine news :

1. Statins effective in long term, Nordic study suggests
2. Statins show early promise for treating multiple sclerosis
3. Statins and aspirin may protect against severe vision loss in elderly
4. Statins may inhibit calcium growth on aortic valve in the elderly
5. International Study Finds Statins Raise Good Cholesterol, Wake Forest Physician Reports
6. Charcoal and forest management could reduce greenhouse gas levels & save lives in Africa
7. Novel therapy tested in mice could chase away cat allergies
8. Costs of antidepressants could have funded effective alternatives
9. Emergency clopidogrel could save thousands of lives46,000-patient heart attack trial results
10. Blood pressure treatment could cut risk of strokes and heart attacks
11. Proteins found in urine of pregnant women could help diagnose preeclampsia

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Statins could reduce stroke risk third

(Date:4/17/2014)... signs of chronic inflammation in non-cancerous prostate tissue may ... cancer than those with no inflammation, according to results ... Johns Hopkins Kimmel Cancer Center. , The link between ... with so-called high-grade prostate cancer those with a ... presence of the most aggressive and rapidly growing prostate ...
(Date:4/17/2014)... a study published today in PLOS Pathogens , ... malaria is common can mount an immune response to ... avoid repeated bouts of high fever and illness and ... bloodstream. The findings may help researchers develop future interventions ... malaria parasite. , Each year, approximately 200 million cases ...
(Date:4/17/2014)... In a review published in the April issue of ... The Feinstein Institute for Medical Research, says it,s time ... approach to treating sepsis, which kills millions ... Sepsis occurs when molecules released into the bloodstream to ... body. Inflammation is necessary for maintaining good health ...
(Date:4/17/2014)... Doctors who treat patients with a severe and ... an agonizing treatment decision. , The drug sirolimus ... relieve shortness of breath. But some patients eventually ... potentially fatal complications following transplantation. , "It,s a ... director of Loyola University Medical Center,s LAM Clinic ...
(Date:4/17/2014)... By discovering a new mechanism that allows blood to ... UC Irvine and the Salk Institute have opened the ... stroke-induced brain damage. , A complex and devastating neurological ... primary reason for disability in the U.S. The blood-brain ... blood-borne material into the brain, causing the permanent deficits ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Study IDs new cause of brain bleeding immediately after stroke 2
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... 2014 HeartWare International, Inc . (NASDAQ: ... miniaturized circulatory support technologies that are revolutionizing the treatment ... revenues for the fourth quarter of 2013 will be ... approximately $208 million. "Our full-year revenue growth ...
(Date:1/14/2014)... 14, 2014 InformEx, North America,s ... chemistry, will hold the 30 th edition of its ... Convention Center from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ... pharmaceutical, fine chemical and specialty chemical companies will take part ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
Cached News: